Results 61 to 70 of about 206,699 (375)

Quantifying Policy Administration Cost in an Active Learning Framework [PDF]

open access: yesarXiv, 2023
This paper proposes a computational model for policy administration. As an organization evolves, new users and resources are gradually placed under the mediation of the access control model. Each time such new entities are added, the policy administrator must deliberate on how the access control policy shall be revised to reflect the new reality.
arxiv  

Review and new therapeutic alternatives for the treatment of cutaneous Leishmaniasis [PDF]

open access: yes, 2014
Podeu consultar el llibre complet a: http://hdl.handle.net/2445/63704Leishmaniasis comprises a group of diseases caused by protozoa of the genus Leishmania and has two basic clinical forms, visceral Leishmaniasis and cutaneous Leishmaniasis. The clinical
Pujol Brugués, Alba   +1 more
core  

Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. [PDF]

open access: yes, 2014
BackgroundCanine cutaneous T-cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are lacking. The novel anticancer nucleotide prodrug VDC-1101 (formerly known as GS-9219) has shown efficacy in dogs with multicentric lymphoma.
Burgess, KE   +5 more
core   +2 more sources

miRNA‐29 regulates epidermal and mesenchymal functions in skin repair

open access: yesFEBS Letters, EarlyView.
miRNA‐29 inhibits cell‐to‐cell and cell‐to‐matrix adhesion by silencing mRNA targets. Adhesion is controlled by complex interactions between many types of molecules coded by mRNAs. This is crucial for keeping together the layers of the skin and for regenerating the skin after wounding.
Lalitha Thiagarajan   +10 more
wiley   +1 more source

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

open access: yesMolecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh   +6 more
wiley   +1 more source

Clonazepam-induced lichenoid drug eruption: a case report

open access: yesBMC Psychiatry, 2021
Background Lichenoid drug eruption is rare and can mimic idiopathic lichen planus and other dermatoses. Clonazepam, a commonly used drug for the treatment of anxiety-related disorders and seizures, is known to be an unlikely cause of cutaneous adverse ...
Hee Won Yang   +3 more
doaj   +1 more source

Germline variants in CDKN2A wild‐type melanoma prone families

open access: yesMolecular Oncology, EarlyView.
Among melanoma‐prone families, wild‐type for CDKN2A and CDK4, some have pathogenic variants in genes not usually linked to melanoma. Furthermore, rare XP‐related variants and variants in MC1R are enriched in such families. Germline pathogenic variants in CDKN2A are well established as an underlying cause of familial malignant melanoma. While pathogenic
Gjertrud T. Iversen   +5 more
wiley   +1 more source

The effect of 17β-estradiol on cutaneous wound healing in protein-malnourished ovariectomized female mouse model.

open access: yesPLoS ONE, 2014
Cutaneous wound healing is delayed by protein malnutrition (PM). On the other hand, estrogen promotes cutaneous wound healing by its anti-inflammatory and cell proliferation effects.
Kanae Mukai   +6 more
doaj   +1 more source

Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature [PDF]

open access: yes, 2019
Drug-induced subacute cutaneous lupus erythematosus (SCLE) is the most common subtype of drug-induced systemic lupus erythematosus and has been associated with more than 100 drugs.
Marsch, Amanda F, Shakhbazova, Anastasia
core  

Structures, targets and recent approaches in anti-leishmanial drug discovery and development. [PDF]

open access: yes, 2011
Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002.
Seifert, Karin
core   +2 more sources

Home - About - Disclaimer - Privacy